VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients
pharmaceutical investing VBI Vaccines Announces Dosing of First Patient in Phase 1/2a Clinical Study of VBI-1901
pharmaceutical investing VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
